The design and discovery of topoisomerase-II inhibitors as new cancer drugs: current strategies and future perspectives
Anjaneyulu Yakkala, Prasanna Shaik, Rahaman Seelam, Bhusi Reddy Vohora, Divya Manga, Vijjulatha Kamal, Ahmed
Anjaneyulu Yakkala, Prasanna
Shaik, Rahaman
Seelam, Bhusi Reddy
Vohora, Divya
Manga, Vijjulatha
Kamal, Ahmed
Citations
Altmetric:
Other Names
Location
Time Period
Advisors
Original Date
Digitization Date
Issue Date
2026-05-25
Type
Article
Genre
Keywords
Clinical trials,Dual inhibitors,Preclinical trials,Small molecules,Topoisomerase II
Subjects (LCSH)
Citation
Anjaneyulu Yakkala, P., Shaik, R., Seelam, B. R., Vohora, D., Manga, V., & Kamal, A. (2026). The design and discovery of topoisomerase-II inhibitors as new cancer drugs: current strategies and future perspectives. Expert Opinion on Drug Discovery, 21(6), 623–653. https://doi.org/10.1080/17460441.2026.2672645
Abstract
Topoisomerases (Topo) are important targets in cancer chemotherapy due to their essential role in regulating DNA topology. Clinically used topoisomerase inhibitors, including poisons and catalytic inhibitors, produce anticancer effects by interfering with these processes. However, their long-term clinical use is often limited by drug resistance, cardiotoxicity, and myelosuppression, highlighting the need for safer and more effective alternatives.
Table of Contents
Description
Click on the DOI link to access this article at the publishers website (may not be free).
Publisher
Taylor & Francis
Journal
Book Title
Series
Digital Collection
Finding Aid URL
Use and Reproduction
Archival Collection
PubMed ID
DOI
ISSN
17460441